Healthcare / Medical Care FacilitiesJakarta
$1705.00
+85.00 (+5.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $958.8B · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$23.71T
P/E
17.2x
↓EV/EBITDA
10.4x
↓ROE
18.8%
↑Gross Margin
54.7%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.9%
FCF CAGR
+50.2%
FCF margin
17.9%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.37T · net income $1.36T · FCF $958.84B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5368.32B | $5368.32B | $4874.37B | $4264.28B | $4048.93B |
| Net Income | $1364.81B | $1364.81B | $1146.35B | $916.13B | $1007.99B |
| EBITDA | $2037.12B | $2037.12B | $1788.51B | $1439.49B | $1535.91B |
| EPS | — | — | 82.43 | 65.08 | 71.61 |
| Gross Margin | 54.7% | 54.7% | 53.7% | 49.9% | 51.3% |
| Operating Margin | 30.8% | 30.8% | 30.2% | 27.5% | 31.9% |
| Net Margin | 25.4% | 25.4% | 23.5% | 21.5% | 24.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Ratio | 4.54 | 4.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $958.84B | $958.84B | $1025.51B | $760.09B | $283.17B |
| Returns | |||||
| ROE | 18.8% | 18.8% | 17.6% | 15.7% | 18.6% |
| Valuation | |||||
| P/E | 17.20 | 17.20 | 30.09 | 39.80 | 39.80 |
| EV/EBITDA | 10.40 | 10.40 | 18.69 | 24.74 | 25.67 |
| P/B | 3.27 | 3.27 | 5.31 | 6.26 | 7.40 |
| Growth & Yield | |||||
| Revenue Growth | 10.1% | 10.1% | 14.3% | 5.3% | — |
| EPS Growth | — | — | 26.7% | -9.1% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.6%
Start / end P/E
n/dx → n/dx
EPS bridge
82.43 → n/d
Residual
-31.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.